Hemophilia :: Wyeth Pharmaceuticals and Nautilus Biotech announce collaboration to develop hemophilia therapies
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Nautilus Biotech in Evry, France, today announced the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for the treatment of hemophilia B.